Zacks Research Upgrades Q32 Bio (NASDAQ:QTTB) to Strong-Buy

Q32 Bio (NASDAQ:QTTB) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Q32 Bio in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Q32 Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Q32 Bio Stock Performance

Shares of NASDAQ QTTB opened at $6.82 on Thursday. The firm’s 50-day moving average price is $4.29 and its 200-day moving average price is $3.15. Q32 Bio has a 52-week low of $1.35 and a 52-week high of $7.80. The company has a market cap of $83.89 million, a PE ratio of 2.97 and a beta of 0.14. The company has a quick ratio of 4.57, a current ratio of 4.85 and a debt-to-equity ratio of 0.08.

Q32 Bio (NASDAQ:QTTB) last released its quarterly earnings data on Tuesday, March 10th. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $4.71. The company had revenue of $53.74 million for the quarter. As a group, analysts anticipate that Q32 Bio will post -12.32 EPS for the current year.

Insider Buying and Selling at Q32 Bio

In other news, CEO Jodie Pope Morrison sold 9,896 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total transaction of $44,630.96. Following the completion of the sale, the chief executive officer owned 89,104 shares of the company’s stock, valued at $401,859.04. The trade was a 10.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 16,706 shares of company stock worth $75,344. Company insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Q32 Bio

A number of institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in Q32 Bio during the fourth quarter valued at about $68,000. Opaleye Management Inc. bought a new position in shares of Q32 Bio in the fourth quarter worth about $708,000. ADAR1 Capital Management LLC purchased a new position in shares of Q32 Bio during the 4th quarter valued at about $66,000. Jane Street Group LLC purchased a new position in shares of Q32 Bio during the 4th quarter valued at about $84,000. Finally, HRT Financial LP grew its stake in shares of Q32 Bio by 66.5% during the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after acquiring an additional 9,862 shares during the period. 31.32% of the stock is owned by institutional investors.

More Q32 Bio News

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright raised multi-year EPS forecasts and reiterated a Buy rating with a $13 price target, trimming losses in near-term years and projecting positive earnings by FY2029–FY2030 (FY2029 $0.16; FY2030 $0.41). This institutional upgrade and target amplify upside expectations.
• Positive Sentiment: Zacks added QTTB to its Rank #1 (Strong Buy) momentum lists on March 13, highlighting renewed buy-side interest and momentum flow into the stock. Best Momentum Stocks to Buy for March 13th
• Positive Sentiment: Zacks also listed QTTB among new Strong Buy additions on March 13, reinforcing short-term analyst-driven demand. New Strong Buy Stocks for March 13th
• Neutral Sentiment: Zacks highlights that analysts’ price targets imply a ~103.6% upside vs. the current level — a bullish headline, but the story notes such consensus upside metrics can be unreliable and should be weighed against operational and clinical risk. Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
• Neutral Sentiment: There’s press coverage on HC Wainwright’s Q1 earnings outlook for Q32 Bio; details may influence near-term expectations once parsed by investors. What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings?
• Negative Sentiment: Despite the analyst upgrades, the sell-side consensus for the current fiscal year remains deeply negative (consensus ~-12.32 EPS), keeping fundamental downside risk and valuation uncertainty elevated — a key reason some investors are selling into rallies.
• Negative Sentiment: Short-term volatility risk remains after the company’s recent unusual EPS print (reported EPS of $3.65 on March 10) and the disparity between that beat and long-term consensus; such divergence can trigger profit-taking and skepticism until guidance/continuity is clear.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.